MedTrace Logo

The Effect of Muscle Stimulation and Amino Acid Intake on Protein Metabolism During Critical Illness

NCT07430969 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-22

No results posted yet for this study

Summary

The goal of this clinical trial is to study how whole-body electrical stimulation combined with amino acid intake affects muscle health in ventilated ICU patients. The main questions to answer are:

* Does electrostimulation improve the balance of muscle protein in ICU patients?
* Does combining electrostimulation with amino acid help build muscle and prevent muscle loss?

Researchers will compare three groups of patients:

1. Sham electrostimulation (no current applied) + the standard nutrition
2. Electrostimulation + the standard nutrition
3. Electrostimulation + a 20g amino acid bolus

Participants will:

* Receive either real or sham electrostimulation
* Get their standard nutrition or a 20g amino acid bolus
* Have marked amino acids given through an IV
* Have blood samples taken to measure the amino acids and glucose in the blood
* Undergo ultrasound of the upper arm to measure the blood flow

Conditions

  • Muscle Wasting in Critically Ill

Interventions

DIETARY_SUPPLEMENT

Amino acid bolus (20g)

A bolus dose of 20 grams of amino acids provided after the NMES intervention to assess the combined effect of muscle stimulation and protein intake on muscle protein metabolism.

OTHER

Standard enteral nutrition

The provision of standard nutritional support, typically administered via enteral feeding tubes.

OTHER

NMES

Active neuromuscular electrical stimulation applied to the entire body to induce muscle contractions through small electric currents.

OTHER

Sham (No Treatment)

A placebo treatment in which no actual electrical stimulation is delivered, serving as a control for the active NMES.

Sponsors & Collaborators

  • Gelderse Vallei Hospital

    collaborator OTHER

  • Wageningen University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-18
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07430969 on ClinicalTrials.gov